We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Exicure Inc (XCUR) USD0.0001

Sell:$0.54 Buy:$0.54 Change: $0.0006 (0.11%)
Market closed |  Prices as at close on 23 April 2024 | Switch to live prices |
Sell:$0.54
Buy:$0.54
Change: $0.0006 (0.11%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 23 April 2024 | Switch to live prices |
Sell:$0.54
Buy:$0.54
Change: $0.0006 (0.11%)
Market closed |  Prices as at close on 23 April 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company is developing nucleic acid therapies targeting ribonucleic acid (RNA) to address both genetic and non-genetic neurological disorders. Its lead program is a non-opioid pain analgesic directed against the genetically validated target SCN9A. It is engaged in discovery efforts across a range of indications and therapeutic targets, such as pain using non-opioid analgesics, as well as rare neurological genetic disorders, including Huntington's disease, Angelman Syndrome, Batten disease, spinocerebellar ataxia, and sporadic amyotrophic lateral sclerosis (ALS). The Company focuses on pursuing out-licensing opportunities for its clinical asset, cavrotolimod, as well as for its preclinical candidates, including the SCN9A program for neuropathic pain.

Contact details

Address:
2430 N. HALSTED ST.
CHICAGO
60614
United States
Telephone:
+1 (847) 6731700
Website:
https://www.exicuretx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
XCUR
ISIN:
US30205M2008
Market cap:
$4.67 million
Shares in issue:
8.65 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Paul Kang
    President, Chief Executive Officer, Director
  • Jiyoung Hwang
    Chief Financial Officer, Company Secretary, Director
  • Joshua Miller
    Chief Accounting Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.